Dr. Ronald G. Nahass, president of ID Care and of the Infectious Diseases Society of America (IDSA), weighed in on widespread concern among medical organizations following recent changes by the CDC’s Advisory Committee on Immunization Practices (ACIP) to the U.S. childhood vaccine schedule that impact long-established guidance on the hepatitis B vaccine. A significant portion of the reported shift involves moving vaccines previously recommended for all children into categories tied to shared clinical decision-making, which includes recommendations for hepatitis B immunization. Many professional societies, including IDSA, issued a statement arguing these updates may sow doubt about an important early-life vaccine and create confusion for families and clinicians regarding the best approach to protect infants.
“This is a significant departure from the historic role ACIP has played in shaping vaccine policy in the United States. Previously, we could expect science to drive decisions, experts to debate evidence, and consensus to lead to shared, clear recommendations,” said the groups’ statement. “That is not the case with the current committee, and this change puts Americans’ health at risk.”
Dr. Nahass joins other infectious disease leaders in emphasizing the need for vaccine policies rooted in clear scientific evidence and consistent processes.
Read full coverage here